Autonomous Military Technology at a “Tipping Point”
Autonomous military technologies that are capable of independently selecting a course of action to achieve a goal are maturing rapidly, the Defense Science Board said in a newly published study.
“Autonomy, fueled by advances in artificial intelligence, has attained a ‘tipping point’ in value,” the DSB study said.
“Autonomy will deliver substantial operational value–in multiple dimensions–across an increasingly broad spectrum of DoD missions, but the DoD must move more rapidly to realize this value. Allies and adversaries alike also have access to increasingly rapid technological advances occurring globally,” the study said.
The Board recommended that the Department of Defense undertake a series of pilot projects “intended to demonstrate the range of benefits of autonomy for the warfighter.”
The Board did not consider catastrophic failures modes associated with autonomous technologies in any depth.
But the study did say that “an autonomous system must be designed so that humans (and/or machines) can straightforwardly determine whether, once it has been deployed, it is operating reliably and within its envelope of competence — and, if not, that appropriate action can be taken.”
See Summer Study on Autonomy, Defense Science Board, June 2016.
Confirmation that the construction of the security perimeter and associated security infrastructure at RAF Lakenheath are still ongoing once again raises questions about whether U.S. nuclear weapons have already been deployed to the base.
Alaskans are sensibly pulling back from the vogue for bans and returning to a western tradition that has worked for more than half a century – one that welcomes innovation but also oversees it closely.
The strength of our nation’s data policy isn’t just in the rules we write, but in how effectively we translate those rules into a system that prioritizes the public good. Join us in this movement to design and build more resilient national data policies.
The human cost is measured in deaths. The financial cost is measured in the $52 billion taxpayers pay annually end stage renal disease – double NASA’s budget.